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Abstract Membrane type-1 matrix metalloproteinase (MT1-
MMP), a key enzyme in cell locomotion, is known to be pri-
marily recruited to the leading edge of migrating cells. This
raises a possibility that the C-terminal cytoplasmic tail of
MT1-MMP interacts with intracellular regulatory proteins,
which modulate translocations of the protease across the cell.
Here, we demonstrated that MT1-MMP via its cytoplasmic tail
directly associates with a chaperone-like compartment-speci¢c
regulator gC1qR. Although a direct functional link between
these two proteins remains uncertain, our observations suggest
that the transient associations of gC1qR with the cytoplasmic
tail of MT1-MMP are likely to be involved in the mechanisms
regulating presentation of the protease at the tumor cell
surface. ( 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Matrix metalloproteinases (MMPs) are a comprehensive
family of zinc enzymes that degrade the extracellular matrix
and cell surface molecules [1,2]. Understanding the function of
these enzymes in carcinogenesis is critical for the design of
anti-cancer pharmaceuticals. A transmembrane domain and
a cytoplasmic tail (CT) of membrane type-1 (MT1)-MMP
associate this abundant membrane-tethered protease with dis-
crete regions of the plasma membrane and the intracellular
milieu, respectively [3]. MT1-MMP has been shown to be
directly involved in cell locomotion and matrix degradation
[4^6] and in the activation pathway of soluble secretory
MMPs, proMMP-2 and proMMP-13 [7^9]. MT1-MMP was
primarily localized to the leading edge of migrating cells
where the protease directly cleaves certain matrix substrates
[10,11]. These observations raise a possibility that the CT of
MT1-MMP interacts with certain proteins of the intracellular
milieu and plays a role in the mechanisms regulating MT1-
MMP function [12,13].
In this report we present evidence that both in vitro and in
breast carcinoma MCF7 cells the CT of MT1-MMP speci¢-
cally interacts with a multifunctional, ubiquitously expressed
mature gC1qR protein (named also as p33 or p32) [14]. Ear-
lier, we have demonstrated that gC1qR directly associates
with the extracellular domain of MT1-MMP and that
gC1qR is susceptible to MT1-MMP proteolysis [15]. Our cur-
rent results indicate that there are two distinct gC1qR-binding
sites in the MT1-MMP molecule, the ¢rst in the extracellular
part and the second in the intracellular CT sequence of the
protease. These independent lines of evidence linking MT1-
MMP to gC1qR suggest a functional signi¢cance of interac-
tions existing between these proteins in tumor cells.
2. Materials and methods
2.1. Antibodies and reagents
The recombinant gC1qR protein and anti-gC1qR murine mAb
60.11 were described earlier [16,17]. Goat anti-rabbit IgG and donkey
anti-mouse IgG conjugated with horseradish peroxidase (HRP), rab-
bit antibody AB815 against the hinge region of MT1-MMP, and
TMB/M were from Chemicon International (Temecula, CA, USA).
Rabbit antibody against the recombinant catalytic domain of MT1-
MMP (catMT) [18] was generated in our laboratory. Control rabbit
and murine IgG, and ExtrAvidin-HRP were from Sigma (St. Louis,
MO, USA).
2.2. Puri¢cation of gC1qR
The (C)RRHGTPRRLLYSERSLLDKV peptide derived from the
sequence of the MT1-MMP’s CT and the (C)YRSRDHRVKTRLP-
LRQSLGL scrambled peptide (1 mg each) were dissolved in 50 Wl
dimethyl sulfoxide (DMSO), mixed with 1 ml 50 mM Tris^HCl,
5 mM ethylenediamine tetraacetic acid (EDTA), pH 8.5, and cova-
lently linked through the cysteine residue (shown in parentheses in the
peptide sequence) to 1 ml of Sulfo-link Coupling gel (Pierce, Rock-
ford, IL, USA). Human breast carcinoma MCF7 cells (1U109) grown
in Dulbecco’s modi¢ed Eagle’s medium (DMEM)/10% fetal calf se-
rum (FCS) were lysed for 1 h in 20 ml of phosphate-bu¡ered saline
(PBS), 1% Triton X-100, 1 mM CaCl2, 1 mM MgCl2, 1 mM phenyl-
methylsulfonyl £uoride (PMSF), 1 Wg/ml leupeptin, 1 Wg/ml pepstatin,
1 Wg/ml aprotinin, pH 7.4. Insoluble material was removed by centri-
fugation at 25 000Ug for 15 min. The supernatant (about 350 mg of
total protein) was split in two equal parts. One part was chromato-
graphed on a 1 ml CT column, and the other was chromatographed
on a 1 ml scrambled peptide column. After loading of the superna-
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tant, the columns were consecutively washed with 20 volumes of the
lysis bu¡er, 20 volumes of the lysis bu¡er containing 0.5 M NaCl and
10 volumes of 10 mM Tris^HCl, pH 8.5. The bound material was
eluted with 0.05% tri£uoroacetic acid (TFA) and collected in 10 frac-
tions (1 ml each). The pH in each fraction was adjusted by adding 5 Wl
of 10% NH4OH. Fractions were 10-fold concentrated on a Speed-Vac.
One tenth of each fraction was used for sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE) analysis.
2.3. Sequence determination
Following SDS^PAGE, the protein band was transferred to an
Immobilon-P membrane (Millipore, Bedford, MA, USA) and sub-
jected to N-terminal microsequencing. In separate experiments, the
protein band was cleaved directly in gel with trypsin. Tryptic peptides
were extracted from the gel and their mass spectra were determined by
matrix-assisted laser desorption ionization-time of £ight (MALDI-
TOF) mass spectrometry using Perseptive Biosystems Voyager DE-
RP mass spectrometer. The ProFound software at http://
129.85.19.192/profound_bin/WebProFound.exe was used to identify
the sequence of the tryptic peptides.
2.4. MT1-MMP constructs and cell transfection
The wild-type MT1-MMP (WT; GeneBank Accession Number
U41078) and the catalytically inactive mutant (E240A) where the
Ala replaced the Glu-240 residue of the enzyme’s active site were
described earlier [13]. The mutagenic primers, 5P-CCTTGCAGTC-
TTCTTCTTCTAACGCCATGGGACCCCC-3P (direct primer) and
5P-GGGGGTCCCATGGCGTTAGAAGAAGAAGACTGCAAGG-
3P (reverse primer), were used to construct MT1-MMP mutant lacking
the CT (vCT) where the AGA triplet encoding the Arg-563 had been
replaced with the TAA stop codon (nucleotides shown in bold indi-
cate the altered codons). Mutagenesis was performed using the Quick-
Change system (Stratagene, San Diego, CA, USA). The cDNA coding
for vCT mutant was further recloned into the pcDNA3-zeo plasmid
(Invitrogen, San Diego, CA, USA) and its structure was con¢rmed by
sequencing.
MCF7 cell lines stably expressing the WT, E240A and vCT con-
structs were isolated as described previously [19,20]. The MT1-MMP-
transfected cell pools of three to six respective positive clones were
generated to avoid any clone-speci¢c e¡ects. Mock cells transfected
with the original pcDNA3-zeo plasmid were generated as a pool of
zeocin-resistant cells. Transfected cells were routinely grown in
DMEM/10% FCS and 0.2 mg/ml zeocin.
2.5. Immunoprecipitation
Cells were surface biotinylated for 1 h with 0.1 mg/ml Sulfo-NHS-
LC-biotin. Labeled cells were solubilized at 5U106^1U107 cells/ml in
triethanolamine-bu¡ered saline (TBS), pH 7.4, containing 50 mM
n-octyl-L-D-glucopyranoside, 1 mM CaCl2, 1 mM MgCl2, 1 mM
PMSF, 1 Wg/ml leupeptin, 1 Wg/ml pepstatin and 1 Wg/ml aprotinin
for 1 h at 4‡C. Insoluble material was removed by centrifugation.
Supernatants were pre-cleared for 2 h at 4‡C with protein A-Agarose
beads (Calbiochem, San Diego, CA, USA). Aliquots (1 mg of total
protein) of pre-cleared supernatants were incubated overnight at 4‡C
with 1^3 Wg of anti-MT1-MMP AB815 or anti-gC1qR mAb 60.11 and
30 Wl of a 50% protein A-Agarose slurry. Following washing, the
beads were boiled with 2USDS sample bu¡er (125 mM Tris^HCl,
pH 6.8, 4% SDS, 0.005% bromophenol blue and 20% glycerol) with
50 mM DTT for 5 min. Eluted proteins were separated by SDS^
PAGE and transferred onto an Immobilon-P membrane. Bands con-
taining biotin-labeled proteins were visualized by using ExtrAvidin-
HRP and TMB/M as a substrate.
2.6. Immunostaining and confocal microscopy
Cells were grown for 48 h in DMEM/10% FCS at 3U104 cells/well
on 8-well Lab-Tek1 II chamber glass slides (Nalge Nunc Interna-
tional, Naperville, IL, USA) pre-coated overnight with 10 Wg/ml
type I collagen. Next, cells were ¢xed in 4% formaldehyde in PBS
for 15 min at room temperature and washed with 0.02% glycine
PBS to quench free aldehyde residues. Cells were permeabilized with
0.1% saponin (Sigma) in PBS, consecutively blocked with 2.5% nor-
mal donkey serum, 1.0% bovine serum albumin (BSA) and 0.1% sap-
onin in PBS for 20 min at room temperature and further incubated
with gC1qR-speci¢c mAb 60.11 and MT1-MMP-speci¢c antibodies
(both at 10 Wg/ml) for 1 h at room temperature. Slides were washed
and successively incubated for 45 min each with a 1:150 dilution of
Alexa-488-conjugated donkey anti-mouse IgG and a 1:150 dilution of
Alexa-594-conjugated donkey or goat anti-rabbit IgG (Molecular
Probes, Eugene, OR, USA). Following washing with PBS, the slides
were mounted in VectaShield antifading embedding medium (Vector
Lab, Burlingame, CA, USA). The samples were studied in the laser
scanning confocal microscope MRC 1024 MP (Bio-Rad) equipped
with Kr/Ar laser. The levels of co-localization of MT1-MMP with
gC1qR were quanti¢ed by the LaserPix program (Bio-Rad) and ex-
pressed as the Pearson’s correlation coe⁄cient.
3. Results
3.1. The CT peptide sequence of MT1-MMP binds gC1qR
Earlier, we have hypothesized that the C-terminal CT of
MT1-MMP directly interacts with certain intracellular pro-
teins [13]. To isolate a putative intracellular partner, we syn-
thesized the (C)RRHGTPRRLLYSERSLLDKV bait peptide
derived from the sequence of the MT1-MMP’s CT and the
(C)YRSRDHRVKTRLPLRQSLGL scrambled control pep-
tide which has the distinct charge distribution. To avoid di-
merization of the peptide and to ensure its correct orientation
on the matrix, the unique Cys-574 of the CT was replaced
with the Ser in both the bait and control peptides (shown in
bold in the peptide sequence). Earlier, the Cys-574 has been
demonstrated to be essential for a disul¢de bridge that links
monomers of MT1-MMP on cell surfaces [13]. We hypothe-
sized that homodimerization of MT1-MMP could eliminate a
complex formation of the protease monomer with its putative,
heterologous intracellular partner. Accordingly, we speci¢cally
selected the CT sequence incapable of stable dimerization and
replaced the Cys-574 in the peptide sequence with the Ser, the
most chemically similar amino acid residue. This approach
was successfully used in the past [21] and, consequently, was
not expected to sharply modify the recognition pro¢le of the
CT peptide. Since Lehti et al. [12] reported mislocalization at
the cell surface of the C-terminally truncated MT1-MMP mu-
tants bearing deletions in the CT, we did not use shortened
peptides as bait in our studies.
Peptides were each immobilized on a solid matrix support
via the thiol group of the corresponding Cys (shown in paren-
theses). The resulting sorbents were used for isolation of the
CT-binding proteins from MCF7 cells. Equal aliquots of the
lysate were chromatographed on each column. After washing
of the columns, the bound material was eluted with 0.05%
TFA and analyzed by SDS^PAGE (Fig. 1A). There was no
speci¢c protein binding to the scrambled peptide. On the con-
trary, a prevalent 33 kDa protein was eluted from the CT
column. The 33 kDa band was subjected to the N-terminal
microsequencing (Fig. 1B). Additionally, the 33 kDa band
was hydrolyzed with trypsin and the resulting proteolytic frag-
ments were analyzed by MALDI-TOF mass spectrometry.
Both the N-terminal sequencing and MALDI-TOF data dem-
onstrated that the 33 kDa band represented the mature
gC1qR protein.
To further substantiate the ability of the CT bait to directly
interact with gC1qR, the recombinant gC1qR protein was
chromatographed on each the CT and scrambled peptide col-
umns. Following washing, the bound material was eluted and
analyzed by SDS^PAGE (Fig. 1C). gC1qR was found in the
sample eluted from the CT column but not in that obtained
from the scrambled peptide column. These results con¢rmed
that gC1qR was capable of binding to the CT of MT1-MMP.
FEBS 26396 28-8-02 Cyaan Magenta Geel Zwart
D.V. Rozanov et al./FEBS Letters 527 (2002) 51^5752
Fig. 1. gC1qR speci¢cally binds the CT peptide bait. A: Puri¢cation of gC1qR from MCF7 cells. The equal aliquots of the cell lysate were
loaded onto the CT and the scrambled peptide column. After washing, the bound proteins were eluted with 0.05% TFA. Fractions were col-
lected and analyzed by reducing SDS^PAGE. Arrow indicates the 33 kDa band subjected to sequence determination. The positions of the mo-
lecular weight markers are on the right in kDa. B: The sequence analysis of the 33 kDa protein. The upper panel: The upper and lower lanes
represent the known N-terminal sequence of gC1qR (GenBank Accession Number CAA53512) and the N-terminal sequence of the 33 kDa
band (italicized), respectively. The bottom panel: MALDI-TOF mass spectrometry analysis of the 33 kDa band. The upper sequence represents
gC1qR. The peptide sequence of the 33 kDa tryptic peptides (italicized) is shown below. C: Chromatography of gC1qR. Equal aliquots of re-
combinant gC1qR (2 Wg each) in 1 ml PBS, pH 7.4, containing 0.005% Brij 35, 1 mM CaCl2, 1 mM MgCl2 were loaded onto each the CT
and the scrambled peptide columns. Columns were consecutively washed with 20 volumes of PBS, pH 7.4, containing 0.005% Brij 35, 1 mM
CaCl2, 1 mM MgCl2, with 10 volumes of the same bu¡er with 0.5 M NaCl and with 10 volumes of 10 mM Tris^HCl bu¡er, pH 8.5. The pro-
tein was eluted with 0.05% TFA. Fractions were collected, concentrated on a Speed-Vac and analyzed by SDS^PAGE. Left, middle and right
lanes show puri¢ed gC1qR, and the samples eluted from the CT and the scrambled peptide columns, respectively. The positions of the molecu-
lar weight markers are on the right in kDa.
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3.2. The CT is essential for co-precipitation of gC1qR with
MT1-MMP
To analyze whether MT1-MMP interacts with cellular
gC1qR, cells stably expressing the WT, E240A or vCT con-
structs were surface labeled with membrane-impermeable bio-
tin and lysed. The cell lysates were immunoprecipitated with
either MT1-MMP- or gC1qR-speci¢c antibodies. Immunopre-
cipitation detected no MT1-MMP in mock cells (Fig. 2A). In
turn, MT1-MMP was readily identi¢ed in cells transfected
with the wild-type and mutant constructs. Consistent with
the earlier observations [12,13,22], the WT protease was rep-
resented by the prominent 39 and 42 kDa stable, catalytically
inactive ectodomain forms. The 72 kDa band was non-speci¢c
since it was present also in mock cells expressing no MT1-
MMP (Fig. 2A, WT and mock). Cells expressing the E240A
mutant exhibited the 60 kDa MT1-MMP since self-proteolysis
of the enzyme was signi¢cantly suppressed. Truncated MT1-
MMP was observed in cells transfected with the vCT con-
struct.
Intriguingly, in cells expressing the proteolytically inert
E240A construct, anti-gC1qR antibody recovered a biotin-la-
beled protein highly similar to MT1-MMP. The relatively low
e⁄ciency of co-precipitation may be explained by the dimer-
ization of MT1-MMP and by the preferential association of
E240A monomers with gC1qR. The same anti-gC1qR anti-
body relatively ine⁄ciently recovered the degraded, catalyti-
cally inactive ectodomain forms of MT1-MMP in WT cells
and failed to precipitate the vCT mutant in vCT cells (Fig.
2A). These ¢ndings suggest that intracellular gC1qR was ca-
pable of e⁄ciently associating the CT of the inactive E240A
construct. In agreement, the vCT mutant lacking the CT se-
quence was unable to bind intracellular gC1qR.
Anti-gC1qR antibody mAb 60.11 did not precipitate biotin-
labeled gC1qR from any tested cell lines (Fig. 2A). Concom-
itantly, £ow cytometry analysis has not revealed any surface
expression of gC1qR in MCF7 cells (data not shown). How-
ever, this antibody e⁄ciently immunoprecipitated unlabeled
gC1qR from cell lysates (Fig. 2B). To verify the presence of
gC1qR in the intracellular compartment, the plasma mem-
brane and cytosol fractions of E240A cells were separated
by the ultracentrifugation at 100 000Ug for 1 h. Immunoblot-
ting employing anti-gC1qR mAb 60.11 demonstrated the
presence of soluble and membrane-integrated gC1qR (Fig.
2B). According to these results, the total amount of soluble
gC1qR exceeded that of the membrane-associated gC1qR
about 40^50-fold. Taken together, these ¢ndings suggested
that there was no gC1qR associated with the surface of
MCF7 cells and that the gC1qR protein observed in our
studies originated from the intracellular compartment.
3.3. Subcellular localization and internalization of MT1-MMP
Given the recent reports that the CT regulates activity of
MT1-MMP by controlling it tra⁄cking to and from the cell
surface [23^25] and our ¢ndings that the CT sequence directly
interacts with gC1qR, we investigated the subcellular local-
ization of MT1-MMP and gC1qR by high-resolution confocal
microscopy. Here, we employed a⁄nity-puri¢ed antibody
against the catMT which recognizes the full-length enzyme
but not the inactive 39 and 42 kDa ectodomain forms lacking
the catalytic domain sequence [22].
Immunostaining experiments demonstrated a predomi-
nantly membrane localization of the proteinase in permeabi-
lized WT, E240A and vCT cells (Fig. 3A^C). Furthermore,
there was an intense staining of the intracellular pool of MT1-
MMP in WT and E240A cells (XZ plans at the bottom part of
Fig. 3A and C). MT1-MMP immunolabeling in E240A cells
resembled the pattern observed in WT cells.
Remarkably, no intracellular pool of MT1-MMP was ob-
served in cells expressing the vCT construct (Fig. 3B; see XZ
plan at the bottom). Further, no MT1-MMP staining was
found at the basal side of the membrane at the sites involved
Fig. 2. gC1qR recovers biotin-labeled MT1-MMP. A: gC1qR co-
precipitates with the catalytically inert full-length E240A mutant.
Mock, WT, E240A and vCT cells were surface labeled with mem-
brane-impermeable biotin and lysed. Cell lysates were each immuno-
precipitated with MT1-MMP- or gC1qR-speci¢c antibodies. The
precipitated material was separated by SDS^PAGE and transferred
to a membrane support. Biotin-labeled proteins were detected by in-
cubating the membrane with ExtrAvidin-HRP followed by incuba-
tion with TMB/M. Note that gC1qR recovers the WT and espe-
cially the E240A but not the CT construct. No speci¢c bands were
detected with control rabbit and murine IgG (data not shown). The
positions of the molecular weight markers are on the left in kDa.
B: gC1qR is present in the membrane and cytosol fractions but not
on the surface of E240A cells. Cells were left untreated (lanes 1, 3,
4) or surface labeled with biotin (lane 2). The gC1qR protein was
immunoprecipitated from the lysates of unlabeled cells with anti-
gC1qR mAb 60.11 and detected after SDS^PAGE and transfer to a
membrane with biotin-labeled mAb 60.11, followed by incubation
with ExtrAvidin-HRP (lane 1). The lysate of biotin-labeled cells
(1 mg total protein) was immunoprecipitated with anti-gC1qR mAb
60.11, the precipitate was electrophoretically separated, and the pro-
teins were identi¢ed by using ExtrAvidin-HRP (lane 2). Unlabeled
2.5U108 cells (lanes 3 and 4) were re-suspended in 20 ml TBS and
the cell suspension was transferred to a Parr cell disruption bomb
(PARP Instrument Co., Moline, IL, USA). The bomb was pressur-
ized with nitrogen to 500 psi for 10 min. Cells were disrupted as the
suspension was released to atmospheric pressure through the dis-
charge valve. The lysate was centrifuged for 15 min at 10 000Ug to
pellet cell debris. Further, the supernatant was spun at 100 000Ug
for 1 h in a Beckman XL-80 ultracentrifuge to separate the mem-
brane fraction from the supernatant (20 ml) largely containing the
soluble cytosolic proteins. The membrane fraction was re-suspended
in 1 ml TBS. The equal aliquots of the membrane fraction (lane 3,
membranes) and the supernatant (lane 4, cytosol) were analyzed by
Western blotting employing anti-gC1qR mAb 60.11 followed by
donkey anti-mouse IgG-HRP. Lane 5, the puri¢ed recombinant
gC1qR (100 ng) stained with mAb 60.11 as described above.
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in attachment of vCT cells to the matrix. The morphology of
vCT cells was clearly distinct from that of other cell types.
Consistent with our earlier observations [13], vCT cells were
rounded suggesting that these mutant cells were incapable of
properly maintaining the cytoskeletal sca¡old (Fig. 3B). Sim-
ilar observations were reported recently by other groups
[12,23,24,26].
The immunocytochemical examination of cells has shown a
conservative distribution of naturally expressed gC1qR at the
regions corresponding to mitochondria, the lumens of endo-
plasmic reticulum and Golgi in mock, WT, E240A and vCT
cells. Intracellular localization of gC1qR was demonstrated by
additional co-staining experiments with mitochondrial, Golgi
and endoplasmic reticulum markers (data not shown). Both
WT and E240A cells demonstrated the similar staining pattern
of gC1qR, especially near the cell membrane where gC1qR
partially co-localized with MT1-MMP (XZ plans at the bot-
tom part of Fig. 3A and C). The gC1qR staining of vCT cells
was distinct from that in other cell types. In vCT cells gC1qR
largely resided in the vicinity of the plasma membrane be-
neath the layer of MT1-MMP rather than in the cytoplasm
(XZ plan at the bottom part of Fig. 3B).
To enhance the visual e¡ect of MT1-MMP co-localization
with gC1qR, color inserts of vertical sections (XZ planes) on
Fig. 3A, B and C were enlarged, split in single monochromatic
channels and shown in Fig. 3D, E and F. In WT and E240A
cells the strong proteinase staining obscured that of gC1qR,
thereby complicating the visual assessment of the images. To
quantitatively evaluate the levels of co-localization of MT1-
MMP with gC1qR, the Pearson’s correlation coe⁄cient was
calculated on stacks of optical sections scanned within single
cells. The values were 0.43, 0.31 and 0.26 for E240A, WT and
vCT cells, respectively, indicating the least antigen overlap
between the vCT mutant and gC1qR.
Since our ¢ndings suggest that the CT is essential both to
the associations with gC1qR and to the presentation of MT1-
MMP at the cell surface, apparently, through regulating the
mechanisms involved in internalization of the protease, we
further assessed internalization of MT1-MMP in WT,
E240A and vCT cells. For these purposes, cells were pre-in-
cubated for 48 h with a potent hydroxamate inhibitor
GM6001 to suppress autolytic processing and shedding of
the protease [22,25] and then surface biotinylated. Further,
labeled cells were each incubated alone or with the inhibitors
of the lysosomal degradation (chloroquine) and of the protein
synthesis (cycloheximide). Under our experimental conditions,
MT1-MMP was predominantly internalized in WT and
E240A cells but not in vCT cells (Fig. 4A). The blocking of
protein synthesis prevented e⁄cient internalization of WT and
E240A constructs suggesting the de novo protein synthesis is
essential for internalization of MT1-MMP. The inhibition of
lysosomal degradation by chloroquine also signi¢cantly ele-
vated the residual levels of membrane-tethered biotin-labeled
MT1-MMP in WT and E240A cells. The e¡ect of chloroquine
indicated that the lysosomal degradation pathway is at least
partially involved in the regulation of MT1-MMP presenta-
Fig. 3. Immuno£uorescence of cells. WT, E240A and vCT cells were each stained with anti-gC1qR mAb 60.11 and anti-catMT antibody (green
and red, respectively). A, B and C: Images of XY projections of cellular clusters. Arrows locate the Y coordinate of the vertical XZ single sec-
tion made through cells. D, E and F: Enlarged images of XZ sections presented at the bottom of A, B and C. Note the presence of the intra-
cellular MT1-MMP pool in WT and E240A cells. Staining with control rabbit and murine IgG was clearly negative (data not shown). The bar,
10 Wm.
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tion on cell surfaces. In contrast, internalization of vCT was
less prominent relative to that of two other constructs. Both
cycloheximide and chloroquine failed to strongly a¡ect the
presentation of the vCT construct on the cell surface suggest-
ing less e⁄cient internalization of vCT.
However, the absence of the CT weakens associations of
MT1-MMP with the plasma membrane, promotes shedding
and accumulation of the soluble forms of the protease in the
cultured medium. Thus, only vCT cells exhibited the soluble
MT1-MMP species in medium while WT and E240 cells failed
to extensive shed the protease (Fig. 4B). Similarly to the re-
cent ¢ndings of other authors [25], inhibition of MT1-MMP
activity by a hydroxamate stabilized the protease, and re-
pressed its autoproteolytic shedding (data not shown). Appar-
ently, by a¡ecting both internalization and shedding, the CT
sequence plays a pleiotropic role in cell surface presentation of
MT1-MMP.
4. Discussion
MT1-MMP plays a major role in matrix degradation and
tumor progression [3,4,10,27]. Following stimulation with
concanavalin A or phorbol esters, MT1-MMP is thought to
be recruited to the plasma membrane by yet unidenti¢ed
mechanisms [26,28^30]. In view of these data it was interesting
to speculate whether the CT of MT1-MMP is capable of
speci¢cally associating with the individual components(s) of
the intracellular milieu. This prompted us to use the CT se-
quence as bait in our attempts to identify the putative intra-
cellular partner(s) of MT1-MMP. We have succeeded in iden-
tifying a novel cellular protein, gC1qR, that interacts with
MT1-MMP in vitro and in cultured cells.
The gC1qR is known to exist in two molecular forms, the
1^282 precursor and the 74^282 mature proteins. The mature
gC1qR is generated by post-transcriptional proteolytic pro-
cessing of the precursor. The gC1qR protein may be found
in mitochondria as well as at the cell membrane, in the cyto-
sol, in the nucleus and in cell microenvironment [14,31].
gC1qR associates with and functions as a compartment-spe-
ci¢c regulator of numerous cellular and viral proteins [14,32^
37]. The alignment of the protein sequences which have been
demonstrated to be involved in the binding with gC1qR such
as the Rev of HIV1, HBcAg, the cytoplasmic portion of ad-
renergic receptor and the neurotransmitter-gated ion channel
segment of GABA (type A) receptor L-subunit with the CT
sequence of MT1-MMP demonstrates their similarity, espe-
cially in relative positions of the Arg residues (Fig. 5). The
sequence alignment suggests that the Arg cluster (nos. 563,
564, 569, 570, and 576) of the MT1-MMP’s CT is speci¢cally
involved in the binding to gC1qR. Since it has been docu-
mented that gC1qR is a regulator of protein kinase C location
and function in rat hepatocytes [33], it is possible that gC1qR
plays a similar function in regulating MT1-MMP.
Our chromatography and co-precipitation studies suggest
that MT1-MMP via its CT peptide sequence is capable of
binding to mature gC1qR, thereby suggesting a role of the
CT in MT1-MMPWgC1qR interactions. These ¢ndings as
well as our data regarding cell surface expression, internal-
ization and shedding of MT1-MMP extend the recent studies
by Jiang et al. [23] who demonstrated the function of the CT
of MT1-MMP in cell surface presentation of the protease.
Although a direct functional link between gC1qR and
MT1-MMP is still uncertain, our data allow us to speculate
that this membrane-tethered protease and cellular gC1qR may
work in concert in vivo. There are a few other potentially
important structural features such as di-leucines which are
likely clathrin-dependent internalization motifs [26] and the
C-terminal Val [30], those might a¡ect tra⁄cking and pre-
sentation of MT1-MMP in cells. The signi¢cance of these
motifs is currently under investigation in our laboratory.
Acknowledgements: This work was supported by NIH Grants
CA83017 and CA77470, California Breast Cancer Program Grant
Fig. 4. The CT a¡ects internalization and shedding of MT1-MMP.
A: The CT-deleted MT1-MMP is less e⁄ciently internalized. Fol-
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